

Ref: FOI/GS/ID 4977

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

27 September 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Sclerosis.

You asked:

1. In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Cladribine (Mavenclad)
Copaxone (glatiramer acetate)
Daclizumab (Zinbryta)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Glatiramer acetate generic [eg Brabio]
Lemtrada (alemtuzumab)
Ocrevus (Ocrelizumab)
Peginterferon beta-1a (Plegridy)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Others
Ampyra (Fampyra)

2. For patients receiving Tysabri (natalizumab) what is the average waiting times to treatment (i.e. once diagnosed and natalizumab selected as DMT of choice, how long do patients wait for their treatment to start)?

Trust response: Data is for May to September 2018

1.

Tecfidera = 8

Rebif = 0

Plegridy	= 2
Copaxone	= 1
Avonex	= 1
Aubagio	= 5

2. Not applicable